Company Encyclopedia
View More
name
Bright Minds Biosciences
DRUG.US
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatry and neurology indications. Bright Minds Biosciences Inc.
1.935 T
DRUG.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Bright Minds Biosciences Inc. (NASDAQ:DRUG) Given Consensus Recommendation of "Buy" by Brokerages

    Bright Minds Biosciences Inc. (NASDAQ:DRUG) has received a consensus "Buy" rating from eight brokerages, with an average 1-year target price of $82.50. Institutional investors have significantly increased their holdings, contributing to a stock surge of nearly 1,500%. The company develops therapeutics for severe diseases, with a market cap of $691.95 million. Despite the "Buy" rating, top analysts suggest other stocks may offer better investment opportunities.

    Market Beat·
    US
    DRUG
    +0.88%
    Market Beat·
    US
    DRUG
    +0.88%

    Bright Minds Biosciences (NASDAQ:DRUG) Reaches New 1-Year High - Here's Why

    Bright Minds Biosciences (NASDAQ:DRUG) reached a new 52-week high, trading at $79.30. Analysts have mixed ratings, with HC Wainwright setting a price target of $85.00 and others downgrading the stock. The company has a market cap of $626.77 million, and institutional investors own 40.52% of the stock. Despite a Buy rating, top analysts suggest better investment options.

    Market Beat·
    US
    DRUG
    +0.88%
    Market Beat·
    US
    DRUG
    +0.88%

    enGene Holdings Inc. to Present at Piper Sandler 37th Annual Healthcare Conference

    enGene Holdings Inc., a clinical-stage genetic medicines company, will present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025. The presentation by Chief Strategy and Operations Officer Alex Nichols, Ph.D., will be available via webcast on the enGene website and archived for 90 days. This announcement was originally published by enGene Holdings Inc. via Business Wire.

    Reuters·
    US
    ENGN
    +5.99%
    Reuters·
    US
    ENGN
    +5.99%

    Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS) | DRUG Stock News

    Bright Minds Biosciences has expanded its Scientific Advisory Board by adding four renowned experts in Prader-Willi Syndrome (PWS) to support its PWS program. The experts include Tania Markovic, Jennifer L. Miller, Elizabeth Roof, and Theresa V. Strong. This expansion follows the company's announcement of its PWS program and the nomination of BMB-105 as a new clinical candidate. The experts will provide guidance on clinical studies aimed at addressing PWS symptoms and developing targeted treatments.

    StockTitan·
    US
    DRUG
    +0.88%
    StockTitan·
    US
    DRUG
    +0.88%

    Bright Minds Biosciences: Strategic Advancements in Serotonergic Therapies and Expansion into Prader-Willi Syndrome

    Bright Minds Biosciences has received a Buy rating from Patrick Trucchio of H.C. Wainwright, with a price target of $85. The company is expanding its focus into Prader-Willi syndrome (PWS) with its candidate BMB-105, leveraging its expertise in serotonergic therapies. The Phase 2a NOVA study for BMB-101 in PWS patients aims to validate the efficacy of 5-HT2C receptor activation, addressing significant unmet medical needs. Trucchio's confidence is based on the company's strategic advancements and potential in developing first-in-class therapies for neurological and psychiatric conditions.

    Tip Ranks·
    US
    DRUG
    +0.88%
    Tip Ranks·
    US
    DRUG
    +0.88%
    Posts
    View More

    Recursion Pharmaceuticals (RXRX) $Recursion Pharmaceuticals(RXRX.US) In-depth Research Report: From Phenotypic Screening to Vertical Integration—Revaluation After Exscientia Acquisition and the New Pa......

    • 0
    © 2025 Longbridge｜Disclaimer